30-Year Trends in the Incidence, Characteristics, and Outcome of Cardiac Sarcoidosis in a Nationwide Cohort
Authors' conclusion
Diagnoses of incident CS have increased exponentially in Finland. Concurrently, the phenotype has turned milder and prognosis better, suggesting detection of CS at an earlier stage of its course.
Study context
- Population
- Patients with cardiac sarcoidosis, nationwide cohort, Finland
- Participants
- 511 patients
- Exposure
- Diagnosis periods 1988–2009 vs 2010–2014 vs 2015–2019
- 1988–2009n = 77reference
- 2010–2014n = 166
- 2015–2019n = 268
- Outcome
- Diagnosed cardiac sarcoidosis (CS) cases by period
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
1988–2009
77
events
2010–2014
166
events
2015–2019
268
events
- 5-year count 2015–2019 vs 1990–1994 (268/2)
- 134-fold
- 5-year count 2015–2019 vs 2000–2004 (268/15)
- 18-fold
Observational data: associations, not effects.
Further findings
VT/VF at presentation
LVEF <50% at presentation
Elevated natriuretic peptides at presentation
Late gadolinium enhancement on MRI (% of LV mass)
- VT/VF at presentation: P < 0.001
- LVEF <50% at presentation: P = 0.010
- Elevated natriuretic peptides at presentation: P < 0.001
- Late gadolinium enhancement on MRI (% of LV mass): P = 0.031
Composite of death, heart transplantation, LV-assisted device implantation or ventricular tachyarrhythmia · 5 years
- 5-year incidence, by diagnosis period in order (1988–2009, 2010–2014, 2015–2019)
- 40% (95% CI: 29%-51%), 32% (95% CI: 25%-39%), and 23% (95% CI: 16%-30%) (P = 0.002)
- Prognostic trend disappeared after adjustment for differences in presenting phenotype
Original publication
30-Year Trends in the Incidence, Characteristics, and Outcome of Cardiac Sarcoidosis in a Nationwide Cohort. JACC Adv. Published 13 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →